STAT3 and COVID-19: In the later phase of COVID-19, the potential dysregulation of the AngII-AT1R pathway downstream of ACE2 could lead to cytokine release syndrome, and the IL-6-STAT3 axis may be the required targeting of cytokine pathways in the treatment in COVID-19 patients [44].